Open Journal Systems

Update of therapies in metastatic urothelial carcinoma

Xieqiao Yan, Xinan Sheng

Article ID: 2088
Vol 4, Issue 2, 2023

DOI: https://doi.org/10.54517/urr.v3i1.2088
VIEWS - 37 (Abstract)

Abstract

The prognosis of metastatic urothelial carcinoma (mUC) is poor, with a median overall survival of about 14 months. Platinum-based chemotherapy has been standard for first-line treatment of mUC for a long time, but there is still no predictive biomarker to help guide treatment and select patients most likely to derive benefit from these regimen. Recent advances in immunotherapy has changed the landscape of mUC, with significant improvement in overall survival among responsible patients. Moreover, the advent of next-generation sequencing has resulted in both an improved understanding of the fundamental genetic changes that characterize mUC and identification of several potential biomarkers and therapies. Within this review, we summarized these emerging novel immunotherapy and targeted therapy, which may improve or have improved the outcomes of mUC.

Keywords

metastatic urothelial carcinoma; immunotherapy; targeted therapy

Full Text:

PDF

References

1. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with metho-trexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer[J]. J Clin Oncol, 2005, 23(21):4602-4608.

2. Bellmunt J, von der MaaseH, Mead GM, et al. Randomized phase Ⅲ study comparing paclitax-el/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987[J]. J Clin Oncol, 2012, 30(10):1107-1113.

3. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembroli-zumab as Second-Line Therapy for Advanced Urothelial Carcinoma[J]. N Engl J Med, 2017, 376(11):1015-1026.

4. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezoli- zumab in patients with locally advanced and metastatic uroth- elial carcinoma who have progressed following treatment with plati-num-based chemotherapy: a single-arm, multicen-tre, phase 2 trial[J]. Lancet, 2016, 387(10031):1909-1920.

5. Powles T, Durán I, van der Heijden MS, et al. Ate-zolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial[J]. Lancet, 2018, 391(10122):748-757.

6. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial car-cinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial[J]. Lancet Oncol, 2016, 17(11):1590-1598.

7. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2017, 18(3):312-322.

8. Massard C, Gordon MS, Sharma S, et al. Safety and Eﬃcacy of Durvalumab (MEDI4736), an An-ti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer[J]. J Clin Oncol, 2016, 34(26):3119-3125.

9. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients with Refractory Metastatic Urothelial Carcinoma: Results from a Multicenter, Phase Ⅰ b Study[J]. J Clin Oncol, 2017, 35(19): 2117-2124.

10. Prendergast GC, Malachowski WP, DuHadaway JB, et al. Discovery of IDO1 Inhibitors: From Bench to Bedside[J]. Cancer Res, 2017, 77(24):6795-6811.

11. Josep T. BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), incombina-tion with nivolumab (NIVO): Updated safety across all tumor cohortsand eﬃcacy in pts with ad-vanced bladder cancer (advBC)[C]. Chicago: AS-CO, 2018.

12. Smith DC, Gajewski T, Hamid O, et al. Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase Ⅰ / Ⅱ results of ECHO-202/KEYNOTE-037[C]. Chicago: ASCO, 2017

13. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2017, 18(11):1483-1492.

14. Balar AV, Galsky MD, Rosenberg JE, et al. Ate-zolizumab as ﬁrst-line treatment in cispla-tin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, mul-ticentre, phase 2 trial[J]. Lancet, 2017, 389(10064):67-76.

15. Tomlinson DC, Baldo O, Hamden P, et al. FGFR3 protein expression and its relationship tomutation status and prognostic variables in bladder cancer[J]. J Pathol, 2007, 213(1):91-98.

16. Robertson AG, Kim J, Al-Ahmadie H, et al. Com-prehensive Molecular Characterization of Mus-cle-Invasive Bladder Cancer[J]. Cell, 2017, 171(3):540-556.e25.

17. Arlene O. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with meta-static or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)[C]. Chicago: AS-CO, 2018.

18. Markus J. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway[C]. Chicago: ASCO, 2018.

19. Pal SK, Rosenberg JE, Keam B, et al. Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations[C]. Chicago: ASCO, 2016.

20. Jonathan ER. Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)[C]. Chicago: ASCO, 2018.

21. Tagawa ST, Ocean AJ, Lam ET, et al. Therapy for chemopr- etreated metastatic urothelial cancer (mUC) with the antibody- drug conjugate (ADC) sacituzumabgovitecan (IMMU-132)[C]. Chicago: ASCO, 2017.

22. Bellmunt J. Antiangiogenesis to curb urothelial cancer[J]. Lancet, 2017, 390(10109):2220-2221.

23. Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 tri-al[J]. Lancet, 2017, 390(10109):2266-2277.

24. Nobuaki Matsubara. A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinumr- efractory ad-vanced or metastatic urothelial carcinoma (UC)[C]. Chicago: ASCO, 2018.

25. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcita-bine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: re-sults of a multicenter phase Ⅱ National Cancer Institute trial[J]. J Clin Oncol, 2007, 25(16):2218-2224.

26. Oudard S, Culine S, Vano Y, et al. Multicentre ran-domised phase Ⅱ trial of gemcitabine ＋ plati-num, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2[J]. Eur J Cancer, 2015, 51(1):45-54.

27. Wülfing C, Machiels JP, Richel DJ, et al. A sin-gle-arm, multicenter, open-label phase 2 study of lapatinib as the second-linetreatment of patients with locally advanced or metastatic transitional cell carcinoma[J]. Cancer, 2009, 115(13):2881-2890.

28. Powles T, Huddart RA, Elliott T, et al. Phase Ⅲ , Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer[J]. J Clin Oncol, 2017, 35(1):48-55.

29. Choudhury NJ, Campanile A, Antic T, et al. Afat-inib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Al-terations[J]. J Clin Oncol, 2016, 34(18):2165-2171.

30. Rosa Nadal. Clinical eﬃcacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipili-mumab (CaboNivoIpi) in patients (pts) with chem-otherapy-refractory metastatic urothelial carcinoma (mUC) either naıve (n) or refractory (r) tocheck-point inhibitor (CPI)[C]. Chicago: ASCO, 2018